SMC
ALT icon

Smith, Moore & Co’s Altimmune ALT Stock Holding History

Smith, Moore & Co’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.7K Buy
+13,205
New +$56.1K ﹤0.01% 557

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Smith, Moore & Co's ALT Position: Q1 2026 in Review

Smith, Moore & Co opened a new position in Altimmune (ALT) in Q1 2026: 13,205 shares worth $40.7K. The stake represents ﹤0.01% of the portfolio and ranks #557 among its holdings.

173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Smith, Moore & Co held 13,205 shares of Altimmune worth $40.7K as of Q1 2026.
  • Altimmune was a new Smith, Moore & Co position in Q1 2026.
  • Altimmune made up ﹤0.01% of Smith, Moore & Co's portfolio in Q1 2026, its #557 holding.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.